

9901188-4
IPDS copy



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 317/44, C07D 233/72, A61K 31/16, 31/415	A1	(11) International Publication Number: WO 98/13340 (43) International Publication Date: 2 April 1998 (02.04.98)
(21) International Application Number: PCT/US97/16348 (22) International Filing Date: 19 September 1997 (19.09.97) (30) Priority Data: 60/026,848 27 September 1996 (27.09.96) US (71) Applicant (for all designated States except US): PHARMACIA & UPJOHN COMPANY [US/US], 301 Henrietta Street, Kalamazoo, MI 49001 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): WARPEHOSKI, Martha, A. [US/US]; 7600 Curry Lane, Portage, MI 49024 (US). HARPER, Donald, E. [US/US]; 11520 Channel Drive, Plainwell, MI 49080 (US). (74) Agent: YANG, Lucy, X.; Intellectual Property Legal Services, Pharmacia & Upjohn Company, 301 Henrietta Street, Kalamazoo, MI 49001 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(54) Title: β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS (I) (57) Abstract The present invention provides a compound of formula (I), or pharmaceutical acceptable salts thereof wherein R₁ is C₄₋₁₂ alkyl, C₄₋₁₂ alkenyl, C₄₋₁₂ alkynyl, -(CH₂)_n-C₃₋₈ cycloalkyl, -(CH₂)_n-aryl or -(CH₂)_n-het; R₂ is C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, -(CH₂)_n-C₃₋₈ cycloalkyl, -(CH₂)_n-C₃₋₈ cycloalkenyl, -(CH₂)_n-aryl, -(CH₂)_n-het, -(CH₂)_n-Q, -(CH₂)_n-X-R₄ or -(CH₂)_n-CHR₅R₆. The compounds are inhibitors of matrix metalloproteinases involved in tissue degradation.		